Abstract

PURPOSE: To determine overall survival (OS), progression-free survival (PFS) and toxicity in a multicenter, real-world data collection using transarterial radioembolization (TARE) with resin microspheres.MATERIALS AND METHODS: 448 patents were treated at 36 centers between 2015-2019. Treatment history, baseline laboratory and imaging, and treatment goal were assessed. OS and PFS were stratified using Barcelona Clinic Liver Cancer (BCLC) and Child Pugh (CP) stratification. Kaplan-Meier analyses compared OS and PFS with 95% confidence intervals. Transplants were tracked. Toxicities were assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5. Cox Proportional Hazard of baseline demographics assessed factors affecting survival.RESULTS: Prior chemoembolization and systemic therapy were used in 107 (26%) and 68 (16%) of patients. Sixty-six patients (19%) were BCLC A and 202, 51, and 26 were BCLC B/C/D. Median OS for BCLC A patients was not reached at 30 months. Median OS for BCLC B/C/D patients was 19.5, 13.6, and 11.5 months (p=0.0006). Median PFS for BCLC A/B/C/D patients was 19.8, 10.0, 6.3, and 5.9 months (p=0.003). Twenty patients underwent transplant representing 14/43 (33%) undergoing bridge and 6/28 (21%) downstaging therapy. Common Grade 3 toxicities were encephalopathy (11/448, 2.5%), hyperbilirubinemia (10/448, 2.2%) and ascites (9/448, 2.0%). Factors predicting longer survival included CP A (X2=4.2, p=0.04) and BCLC A (X2=5.2, p=0.02).CONCLUSION: In a frequently pretreated patient cohort with disease burden in 81% beyond Milan criteria, TARE with resin microspheres provided OS comparable to other studies in this multicenter review.

View details for DOI 10.1016/j.jvir.2021.03.535

View details for PubMedID 33812981